TScan Therapeutics Secures $52.5 Million Loan from Silicon Valley Bank
WALTHAM, Mass. — TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company dedicated to developing innovative therapies for cancer treatment, has announced an exciting milestone. The company has entered into a term loan facility with Silicon Valley Bank (SVB) that offers up to $52.5 million, marking a significant opportunity for growth and advancement in their mission.
Loan Details and Future Plans
Under this financing agreement, TScan has received an initial $32.5 million to retire existing convertible debt with K2 Health Ventures. This strategic move will not only reduce their debt burden but also provide the company with additional resources to support its operational activities. The loan agreement includes a second tranche of $20 million, which TScan can access until June 30, 2026, contingent upon meeting specific conditions.
The term loans will carry an interest rate pegged at 7.00% or the prime rate minus 0.75%, whichever is higher. Moreover, it has an interest rate cap set at 9.75%. TScan is set to benefit from an extended interest-only payment period for up to two years, granting financial flexibility as it continues to achieve critical milestones in its clinical programs.
Statements from Company Leadership
Jason A. Amello, the Chief Financial Officer of TScan, expressed enthusiasm regarding the refinancing. He stated, "This non-dilutive agreement with SVB allows us to significantly extend the interest-only period and maturity of our debt financing, providing TScan with added financial flexibility and liquidity.” This development indicates that TScan is well-positioned to use its cash resources to support operations through the latter part of 2026, ensuring that they remain on track to deliver therapies that could transform patient care.
Lauren Cole, Managing Director at SVB Life Science and Healthcare Practice, echoed this sentiment, stating, “We’re excited to partner with TScan as they advance their innovative hematology and solid tumor programs.” This commitment from SVB underscores the bank's support of TScan's aspirations and its potential to positively impact the lives of cancer patients.
About TScan Therapeutics, Inc.
TScan is at the forefront of cancer treatment, focusing on T cell receptor-engineered T cell (TCR-T) therapies aimed at treating a variety of cancers. Their lead candidates are entangled with groundbreaking clinical trials, including the ALLOHA Phase 1 heme trial, which targets hematologic malignancies. In addition, TScan’s ImmunoBank continues to grow, holding a repository of therapeutic TCRs that can address multiple HLA types, advancing their capabilities in developing custom therapies for diverse cancers.
About Silicon Valley Bank
Silicon Valley Bank, operating as a division of First Citizens Bank, stands out as a key player in supporting innovative firms across sectors like technology, healthcare, and venture capital. SVB's focus on deep sector expertise aids companies like TScan in navigating their unique challenges and leveraging emerging opportunities in their respective fields.
Frequently Asked Questions
What is the purpose of the loan received by TScan Therapeutics?
The loan is intended to retire existing convertible debt and support TScan's ongoing corporate needs, providing a cushion for their operating plan.
How much funding did TScan receive initially from the loan?
TScan received an initial funding of $32.5 million from the term loan facility.
What are the milestones TScan aims to achieve with this loan?
The loan will help TScan continue developing its clinical programs and reach critical financial and clinical milestones in its cancer treatment research.
What interest rate applies to the term loans?
The borrowings will bear interest at a rate of either 7.00% or the prime rate minus 0.75%, with a cap of 9.75%.
Who is the strategic partner behind the loan agreement?
The strategic partner for the loan is Silicon Valley Bank, a bank that focuses on innovative companies in various industries.
